Last reviewed · How we verify
NCT06752460: Spray B
Evaluation of the EF192B Protection Versus No Treatment
NA trial testing EF192B in Skin Lesions in 72 participants. Not yet recruiting.
31 October 2025
Quick facts
| Lead sponsor | Eurofarma Laboratorios S.A. |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 31 August 2025 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- EF192B
Conditions studied
- Skin Lesions — all drugs for Skin Lesions →
- Skin Care — all drugs for Skin Care →
Sponsor
Eurofarma Laboratorios S.A. — full company profile →
Who can join
Adults 18 to 70, any sex, with Skin Lesions or Skin Care. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was designed with the objective of evaluating the protection potential provided by the experimental product EF192B by evaluating its barrier formation capacity. Once its ability to form a barrier is confirmed, EF192B ability to protect against small skin injuries, such as small cuts, bruises, blisters and cracks is confirmed. The barrier formation also guarantees protection against the formation of calluses.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06752460
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Eurofarma Laboratorios S.A. trials
Trials by the same sponsor.
- NCT07529977 — Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. · Phase 3 · not yet recruiting
- NCT06560333 — iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TR · Phase 3 · withdrawn
- NCT06546735 — Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prost · Phase 3 · not yet recruiting
- NCT06608472 — Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension · Phase 3 · not yet recruiting
- NCT05683574 — Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil · Phase 3 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06752460 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eurofarma Laboratorios S.A.
- Last refreshed: 30 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06752460.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing